The aim of the present study is to investigate the antitumor activity of ganetespib in combination with lapatinib on HER2 + breast cancer cells, as well as the anti-resistance activity of ganetespib alone and in combination with lapatinib in lapatinib-resistant cell lines. This evidence concerns the gene ERBB2 and breast carcinoma.